Director at Aligos (ALGS) granted option on 5,860 common shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Aligos Therapeutics director James Paul Scopa received a new stock option grant covering 5,860 shares of common stock. The options have an exercise price of $5.50 per share and expire on June 25, 2036.
The grant vests and becomes fully exercisable as to 100% of the 5,860 shares on the earlier of the first anniversary of the grant date or immediately prior to Aligos Therapeutics' 2027 annual stockholder meeting, provided Scopa continues serving the company through that vesting date. This is a compensation-related award, not an open-market stock purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Scopa James Paul
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 5,860 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,860 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 5,860 options
Exercise price: $5.50 per share
Expiration date: June 25, 2036
+2 more
5 metrics
Option grant size
5,860 options
Shares of common stock underlying new option award
Exercise price
$5.50 per share
Stock option exercise price for 5,860-share grant
Expiration date
June 25, 2036
Option term end date for this grant
Vesting condition
100% on earlier of 1-year or 2027 meeting
Subject to continuous service through vesting date
Post-grant derivative holdings
5,860 options
Total options held following this reported transaction
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "5.5000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-25T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The shares subject to the option will vest and become exercisable as to 100%..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"subject to continuous service to the Issuer through such vesting date"
FAQ
What did Aligos Therapeutics (ALGS) director James Paul Scopa report in this Form 4?
Director James Paul Scopa reported receiving a stock option grant for 5,860 shares of Aligos Therapeutics common stock. The award is compensation-related, not an open-market trade, and gives him the right to buy shares at a fixed exercise price if vesting conditions are met.
What is the exercise price of James Paul Scopa’s Aligos Therapeutics (ALGS) stock options?
The stock options have an exercise price of $5.50 per share. This means that once the options vest, Scopa can buy Aligos Therapeutics common shares at $5.50 each, regardless of the market price at that future time.
When do James Paul Scopa’s Aligos Therapeutics (ALGS) options vest?
The options vest 100% on the earlier of the first anniversary of the grant date or immediately before the company’s 2027 annual stockholder meeting. Vesting is conditioned on Scopa maintaining continuous service with Aligos Therapeutics through that chosen vesting date.
When do the newly granted Aligos Therapeutics (ALGS) options to James Paul Scopa expire?
The options expire on June 25, 2036. After that expiration date, any unexercised portion of the 5,860-share option grant will lapse, and Scopa would no longer be able to purchase shares under this particular award.